Relapsed, Refractory
Showing 26 - 50 of >10,000
Relapsed/Refractory Acute Myeloid Leukemia Trial in Hefei (gdT cell injection targeting B7-H3 chimeric antigen receptor)
Recruiting
- Relapsed/Refractory Acute Myeloid Leukemia
- gdT cell injection targeting B7-H3 chimeric antigen receptor
-
Hefei, Anhui, ChinaPersonGen Anke Cellular Therapeutice Co., Ltd.
Jan 31, 2023
AML/MDS, Acute Myeloid Leukemia, MDS Trial (Danvatirsen, Danvatirsen + Venetoclax)
Not yet recruiting
- AML/MDS
- +2 more
- Danvatirsen
- Danvatirsen + Venetoclax
- (no location specified)
Aug 14, 2023
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (CB-012)
Not yet recruiting
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- (no location specified)
Nov 9, 2023
Relapsed/Refractory Diffuse Large B Cell Lymphoma Trial in Seoul (Glofitamab, Poseltinib, Lenalidomide)
Recruiting
- Relapsed/Refractory Diffuse Large B Cell Lymphoma
- Glofitamab, Poseltinib, Lenalidomide
-
Seoul, Korea, Republic ofSeoul National University Hospital
Nov 28, 2022
Relapsed/Refractory Lymphoma Trial in Shanghai (tazemetostat, HMPL-689)
Not yet recruiting
- Relapsed/Refractory Lymphoma
-
Shanghai, ChinaRuijin Hospital, Shanghai Jiaotong University School of Medicine
Feb 2, 2023
Lymphoma Trial in Yerevan (Balstilimab)
Not yet recruiting
- Lymphoma
-
Yerevan, ArmeniaHematology Center named after prof. R. Yeolyan
May 26, 2023
Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,
Recruiting
- Diffuse Large B-cell Lymphoma Recurrent
- Diffuse Large B Cell Lymphoma Refractory
- Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Oct 12, 2023
Relapsed/Refractory Large B-Cell Lymphoma Trial in Beijing, Hangzhou (Prizloncabtagene autoleucel)
Recruiting
- Relapsed/Refractory Large B-Cell Lymphoma
- Prizloncabtagene autoleucel
-
Beijing, China
- +1 more
Mar 24, 2023
PD-1 Refractory Advanced Melanoma Trial in Pittsburgh (Responder-Derived Fecal microbiota transplantation (R-FMT, Pembrolizumab,
Not yet recruiting
- PD-1 Refractory Advanced Melanoma
- Responder-Derived Fecal microbiota transplantation (R-FMT
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Sep 1, 2023
B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)
Not yet recruiting
- B-cell Acute Lymphoblastic Leukemia
- (no location specified)
Oct 10, 2023
Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt
Not yet recruiting
- Relapsed/Refractory Waldenstrom Macroglobulinemia
- +3 more
- Brexucabtagene Autoleucel
- +2 more
- (no location specified)
Sep 8, 2022
Relapsed/Refractory Large Granular T Lymphocytic Leukemia Trial in Zhoukou, Tianjin (Linperlisib)
Not yet recruiting
- Relapsed/Refractory Large Granular T Lymphocytic Leukemia
-
Zhoukou, Henan, China
- +1 more
Dec 22, 2022
B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia Trial (Blinatumomab)
Not yet recruiting
- B Precursor Acute Lymphoblastic Leukemia
- Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
- (no location specified)
Sep 25, 2023
CNS Lymphoma Trial in Shanghai (Orelabrutinib, Rituximab, Chemotherapy)
Not yet recruiting
- CNS Lymphoma
- Orelabrutinib
- +2 more
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
Jun 22, 2023
Peripheral T Cell Lymphoma Trial in Zhengzhou (SHR0302)
Not yet recruiting
- Peripheral T Cell Lymphoma
-
Zhengzhou, Henan, ChinaHenan cancer hospital
Jun 2, 2023
Multiple Myeloma Trial in Xuzhou (APRIL-BAFF-Bicephali CAR-T cells)
Recruiting
- Multiple Myeloma
- APRIL-BAFF-Bicephali CAR-T cells
-
Xuzhou, Jiangsu, ChinaKailin Xu
Nov 14, 2023
CAR-T Retreatment Trial in Shanghai (axi-cel)
Recruiting
- CAR-T Retreatment
-
Shanghai, Shanghai, ChinaRuijin Hospital, Shanghai Jiao Tong University School of Medicin
Mar 23, 2023
Relapsed/Refractory Immune Thrombocytopenia Trial in Seoul (Bortezomib)
Not yet recruiting
- Relapsed/Refractory Immune Thrombocytopenia
-
Seoul, Korea, Republic of
- +1 more
Oct 30, 2022
Relapsed/Refractory Large B-cell Lymphoma Trial (KITE-197, Cyclophosphamide, Fludarabine)
Not yet recruiting
- Relapsed/Refractory Large B-cell Lymphoma
- KITE-197
- +2 more
- (no location specified)
Oct 6, 2023
Multiple Myeloma Trial in Houston (Belumosudil mesylate)
Not yet recruiting
- Multiple Myeloma
- Belumosudil mesylate
-
Houston, TexasM D Anderson Cancer Center
Oct 31, 2023
Lymphoma Trial in Beijing (CD70-targeting CAR-T cells)
Recruiting
- Lymphoma
- CD70-targeting CAR-T cells
-
Beijing, Biotherapeutic Department Of Chinsese PLA Gereral Hospital, ChinaChina
Jul 9, 2023
Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Tumor (BPDCN), Relapse Leukemia Trial in Taiyuan (CD123 targeted
Recruiting
- Acute Myeloid Leukemia
- +3 more
- CD123 targeted CAR-NK cells
-
Taiyuan, Shanxi, ChinaShanxi Bethune Hospital
Aug 28, 2023
Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia Trial (CAR-T (CAR-GPRC5D))
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
- Plasma Cell Leukemia
- CAR-T (CAR-GPRC5D)
- (no location specified)
Feb 26, 2023
Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory DLBCL Trial in United States (EZM0414)
Recruiting
- Relapsed/Refractory Multiple Myeloma
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
-
Chevy Chase, Maryland
- +10 more
Jan 12, 2023
T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)
Not yet recruiting
- T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- CD7-CART01
- (no location specified)
Sep 26, 2023